Evidence map›Paper›PMID 21258105›Full record

ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2011

Induction therapy with protease-inhibitors modifies the effect of nevirapine resistance on virologic response to nevirapine-based HAART in children.

Anitha Moorthy, Louise Kuhn, Ashraf Coovadia, Tammy Meyers, Renate Strehlau, Gayle Sherman, Wei-Yann Tsai, Ya Hui Chen, Elaine J Abrams, Deborah Persaud

Registry-linked trialAbstract read
In one paragraph

Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02348177 (A Pharmacokinetics Study Comparing Lopinavir Plasma Exposure When Given as Lopinavir/Ritonavir), which is not on this map. Cited by 16 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 1 pooled it
1.8field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02348177 phase4completednot on this mapstarted 2013, after this paper: background citation

A Pharmacokinetics Study Comparing Lopinavir Plasma Exposure When Given as Lopinavir/Ritonavir (1:1) in the Presence of Rifampicin and Lopinavir/Ritonavir (4:1) Without Rifampicin in HIV and TB Co-infected Children in South Africa.

TypeinterventionalSponsorDrugs for Neglected DiseasesRan2013 to 2016Enrolled96ConditionsAcquired Immunodeficiency Syndrome, TuberculosisArmslopinavir with ritonavir in 1:1 ratio, Lopinavir/ritonavir 4:1
3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 1 synthesis or guideline pooled it, 24 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 3 countries.

Anitha MoorthyJohns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
Louise Kuhn
Ashraf Coovadia
Tammy Meyers
Renate Strehlau
Gayle Sherman
Wei-Yann Tsai
Ya Hui Chen
Elaine J Abrams
Deborah Persaud
Columbia University · USMother Hospital · INUniversity of Maryland, Baltimore · USJohns Hopkins University · USUniversity of the Witwatersrand · ZA

Funding

Clinical Relevance of Transient Nevirapine ResistanceR01HD047177 · NICHD · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI KUHN, LOUISE · 2004 to 2008
$2.6M
HIV-1 chemoprophylaxis and archived drug resistance in infantsR01HD057784 · NICHD · JOHNS HOPKINS UNIVERSITY · PI PERSAUD, DEBORAH · 2007 to 2010
$2.3M
NICHD NIH HHS HD47177NICHD NIH HHS R01 HD047177NICHD NIH HHS R01 HD057784NICHD NIH HHS R01HD057784-04
6 · The paper itself

Abstract

backgroundNevirapine resistance after failed prophylaxis to prevent mother-to-child human immunodeficiency virus (HIV) transmission can compromise subsequent nevirapine-based highly active antiretroviral therapy (HAART).

methodsNevirapine-exposed children who achieved virologic suppression with lopinavir/ritonavir-based induction HAART before switch to nevirapine-based HAART or who continued the lopinavir/ritonavir regimen were studied. Nevirapine-resistant HIV was quantified (≥ 1% frequency) in plasma before therapy and archived in peripheral blood mononuclear cells after induction HAART with ultradeep pyrosequencing. The primary endpoint was virologic failure (confirmed viremia ≥ 1000 copies/mL by 52 weeks) on nevirapine-based HAART, and Receiver operating characteristic analysis identified threshold levels of resistance associated with failure.

resultsNevirapine resistance mutations were detected in plasma at a median frequency of 25.6% in 41 (33%) of 124 children starting HAART at median 9 months of age. After a median nine months of induction HAART, nevirapine-resistant HIV remained archived in cells in 59 (61%) of 96 children (median 13.6% of cells). The threshold frequency of nevirapine resistance in plasma most predictive of virologic failure on nevirapine-based HAART was 25%. Children maintaining resistance before therapy at or above this threshold frequency had a 3.5 fold higher risk of failure (95% confidence interval, 1.1-10.8) than children without detectable plasma resistance. In contrast, virologic failure was not independently associated with age, resistance in plasma below 25% frequencies, or archived in cells.

conclusionsVirologic suppression with lopinavir/ritonavir-based HAART in nevirapine-exposed children raises the threshold level of resistance at which reuse of nevirapine-based therapy is compromised. Standard genotyping may allow identification of children likely to benefit from an induction-switch approach.

Indexed as

Drug Resistance, ViralAntiretroviral Therapy, Highly ActiveChild, PreschoolFemaleGenotypeHIVHIV InfectionsHIV Protease InhibitorsHumansInfantMaleNevirapineRNA, ViralTreatment OutcomeViral LoadViremiaHIV Protease InhibitorsNevirapineRNA, Viral

Identifiers

PMID21258105
PMCPMC3060899
OpenAlexW2169221951

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.